In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device and Diagnostics Dealmaking Quarterly Statistics, Q4 2011

Executive Summary

Medical device companies raised $800 million in the fourth quarter of 2011, and venture capital represented half of that amount. Just over $4 billion was spent to acquire medical device companies, down 50% from Q3’s $8 billion. In vitro diagnostics/research financings were well above the previous quarter, raking in a total of $269 million, with late-stage rounds again bringing in most of the Q4 money. Only five M&A deals were completed, totalling $915 million – way down from Q3’s $2.8 billion for the same number of deals.

You may also be interested in...



Bard Buys Lutonix For Lead In Race To U.S. Market With Drug-Coated Balloon

Deal worth up to $325 million makes Bard first in line to enter the U.S. market with a drug-coated balloon. Firm anticipates PMA submission for Moxy in 2014.

Fujifilm Gains Handheld Ultrasound Devices With SonoSite Acquisition

Imaging device maker Fujifilm buys SonoSite for $995 million, gaining handheld ultrasound devices including Edge, M-Turbo, MicroMaxx and NanoMaxx systems for applications including critical care, musculoskeletal, ob/gyn, vascular, cardiac and superficial imaging.

Salix Expects Acquisition Of Oceana, Two Products, To Be Quickly Accretive

Although privately held Oceana’s two products – Solesta and Deflux – are regulated by FDA as Class III medical devices, Salix intends to market them with existing sales forces.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel